Vybion (Ithaca, NY) is a development-stage biotechnology company with a proprietary biopharmaceutical drug pipeline and platform technology for human monoclonal antibody-like molecule selection and affinity maturation, called ProCode. The company’s contract division has developed over 150 recombinant proteins in multiple expression systems, including 12 biologic drugs in various phases of clinical development. ProCode is being used commercially for Diagnostic and Biomarker product development with a rapid timeline of 10-12 weeks from target to affinity-matured, highly stable products. It has been used successfully where other technologies have failed; ProCode antibody molecules can be rapidly engineered for multiple platform formats and readouts. ProCode has also been used to develop a therapeutic product for Huntington’s disease that targets the cause of Huntington’s can prevent the progression of neuropathology. More information is available at www.vybion.com.
Corgenix and Vybion are members of the Viral Hemorrhagic Fever Consortium, working to develop state-of-the-art diagnostic products for biothreat agents and emerging pathogens.